HCV infections can now be completely cured, thanks to the currently marketed direct-acting antivirals (DAAs). It is known that HCV patients carry viral populations with baseline polymorphisms and/or mutations that make them resistant against some of these DAAs, which can negatively impact the patient's treatment outcome. Using complete HCV coding sequences isolated from 1,306 treatment-naive patients of genotypes (GTs) 1, 2, 3, 4 and 6 from around the globe, we studied the prevalence of baseline resistance-associated polymorphisms (RAPs) and resistance mutations (RMs) against DAAs that are currently on the market or in clinical trials.
Methods
The HCV genome sequences used in this study were retrieved from the NCBI database. RAPs and RMs, with reference to HCV GT1a, were identified using the HCV Geno2pheno web server.
Results
Nearly 50% of the total amino acid positions (including NS3 protease, NS5A and NS5B) studied are baseline polymorphisms that differentiated one GT from the rest. A proportion of these baseline polymorphisms and baseline non-polymorphic RMs could confer a significant increase in resistance against DAAs.
Conclusions
In this study, we show the presence and prevalence of RAPs and RMs in DAA treatment-naive patients against currently used DAAs or DAAs in clinical trials. Our study suggests that RAPs and RMs profiling of HCV patients should be performed before the start of the therapy. Our results should be relevant especially in low- and middle-income countries, where the patients have a large variation of GTs and subtypes, and where the generic HCV treatment is now increasingly available.
References
1.
HoughtonM.Discovery of the hepatitis C virus.Liver Int2009; 29Suppl 2: 82–88.
2.
BlachS., ZeuzemS., MannsM.Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study.Lancet Gastroenterol Hepatol2017; 2: 161–176.
DimitrovaM., ImbertI., KienyM.P.Protein-protein interactions between hepatitis C virus nonstructural proteins.J Virol2003; 77: 5401–5414.
5.
TellinghuisenT.L., FossK.L., TreadawayJ.Regulation of hepatitis C virion production via phosphorylation of the NS5A protein.PLoS Pathog2008; 4: e1000032.
6.
ShimakamiT., HijikataM., LuoH.Effect of interaction between hepatitis C virus NS5A and NS5B on hepatitis C virus RNA replication with the hepatitis C virus replicon.J Virol2004; 78: 2738–2748.
7.
NakanoT., LauG.M.G., LauG.M.L.An updated analysis of hepatitis C virus genotypes and subtypes based on the complete coding region.Liver Int2012; 32: 339–345.
8.
MessinaJ.P., HumphreysI., FlaxmanA.Global distribution and prevalence of hepatitis C virus genotypes.Hepatology2015; 61: 77–87.
9.
MannsM.P., McHutchisonJ.G., GordonS.C.Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.Lancet2001; 358: 958–965.
10.
SvarovskaiaE.S., Dvory-SobolH., ParkinN.Infrequent development of resistance in genotype 1–6 hepatitis C virus-infected subjects treated with sofosbuvir in Phase 2 and 3 clinical trials.Clin Infect Dis2014; 59: 1666–1674.
11.
HerbstD.A., ReddyK.R.Sofosbuvir, a nucleotide polymerase inhibitor, for the treatment of chronic hepatitis C virus infection.Expert Opin Investig Drugs2013; 22: 527–536.
12.
Benítez-GutiérrezL., BarreiroP., LabargaP.Prevention and management of treatment failure to new oral hepatitis C drugs.Expert Opin Pharmacother2016; 17: 1215–1223.
13.
KuntzenT., TimmJ., BericalA.Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naive patients.Hepatology2008; 48: 1769–1778.
14.
PalanisamyN., DanielssonA., KokkulaC.Implications of baseline polymorphisms for potential resistance to NS3 protease inhibitors in hepatitis C virus genotypes 1a, 2b and 3a.Antiviral Res2013; 99: 12–17.
15.
LindströmI., KjellinM., PalanisamyN.Prevalence of polymorphisms with significant resistance to NS5A inhibitors in treatment-naive patients with hepatitis C virus genotypes 1a and 3a in Sweden.Infect Dis (Lond)2015; 47: 555–562.
16.
KosakaK., ImamuraM., HayesC.N.Emergence of resistant variants detected by ultra-deep sequencing after asunaprevir and daclatasvir combination therapy in patients infected with hepatitis C virus genotype 1.J Viral Hepat2015; 22: 158–165.
17.
ItakuraJ., KurosakiM., HasebeC.Complex pattern of resistance-associated substitutions of hepatitis C virus after daclatasvir/asunaprevir treatment failure.PLoS One2016; 11: e0165339.
18.
LenzO., VerbinnenT., FeveryB.Virology analyses of HCV isolates from genotype 1-infected patients treated with simeprevir plus peginterferon/ribavirin in Phase IIb/III studies.J Hepatol2015; 62: 1008–1014.
19.
Di MaioV.C., CentoV., MirabelliC.Hepatitis C virus genetic variability and the presence of NS5B resistance-associated mutations as natural polymorphisms in selected genotypes could affect the response to NS5B inhibitors.Antimicrob Agents Chemother2014; 58: 2781–2797.
20.
ChenZ.W., LiH., RenH.Global prevalence of preexisting HCV variants resistant to direct-acting antiviral agents (DAAs): mining the GenBank HCV genome data.Sci Rep2016; 6: 20310.
21.
KalaghatgiP., SikorskiA.M., KnopsE.Geno2pheno[HCV] – a web-based interpretation system to support hepatitis C treatment decisions in the era of direct-acting antiviral agents.PLoS One2016; 11: e0155869.
22.
de OliveiraT., DeforcheK., CassolS.An automated genotyping system for analysis of HIV-1 and other microbial sequences.Bioinformatics2005; 21: 3797–3800.
23.
AlcantaraL.C.J., CassolS., LibinP.A standardized framework for accurate, high-throughput genotyping of recombinant and non-recombinant viral sequences.Nucleic Acids Res2009; 37: W634–W642.
24.
LontokE., HarringtonP., HoweA.Hepatitis C virus drug resistance-associated substitutions: state of the art summary.Hepatology2015; 62: 1623–1632.
25.
LawitzE., MatusowG., DeJesusE.Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: a Phase 3 study (OPTIMIST-2).Hepatology2016; 64: 360–369.
26.
HeY., KingM.S., KempfD.J.Relative replication capacity and selective advantage profiles of protease inhibitor-resistant hepatitis C virus (HCV) NS3 protease mutants in the HCV genotype 1b replicon system.Antimicrob Agents Chemother2008; 52: 1101–1110.
27.
LenzO., VijgenL., BerkeJ.M.Virologic response and characterisation of HCV genotype 2–6 in patients receiving TMC435 monotherapy (study TMC435-C202).J Hepatol2013; 58: 445–451.
28.
WylesD.L., LuetkemeyerA.F.Understanding hepatitis C virus drug resistance: clinical implications for current and future regimens.Top Antivir Med2017; 25: 103–109.
29.
FridellR.A., QiuD., WangC.Resistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in vitro replicon system.Antimicrob Agents Chemother2010; 54: 3641–3650.
30.
HernandezD., ZhouN., UelandJ.Natural prevalence of NS5A polymorphisms in subjects infected with hepatitis C virus genotype 3 and their effects on the antiviral activity of NS5A inhibitors.J Clin Virol2013; 57: 13–18.
31.
NgT.I., KrishnanP., Pilot-MatiasT.In vitro antiviral activity and resistance profile of the next-generation hepatitis C virus NS5A inhibitor pibrentasvir.Antimicrob Agents Chemother2017; 61: e02558–16.
32.
Dvory-SobolH., VoitenleitnerC., MaberyE.Clinical and in vitro resistance to GS-9669, a thumb site II nonnucleoside inhibitor of the hepatitis C virus NS5B polymerase.Antimicrob Agents Chemother2014; 58: 6599–6606.
33.
LinC., GatesC.A., RaoB.G.In vitro studies of cross-resistance mutations against two hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061.J Biol Chem2005; 280: 36784–36791.
34.
NgT., LuL., ReischT.Resistance selection using glecaprevir and pibrentasvir in replicons of major hepatitis C virus genotypes.J Hepatol2017; 66: S324.
35.
ReauN., NguyenM.H., KowdleyK.V.Integrated resistance analyses of HCV-infected patients treated with sofosbuvir, velpatasvir, and voxilaprevir for 8 and 12 weeks from Phase 2 Studies.AASLD The Liver Meeting. 11–15 November 2016, Boston, MA, USA. Abstract 846.
36.
LawitzE., YangJ.C., StammL.M.Characterization of HCV resistance from a 3-day monotherapy study of voxilaprevir, a novel pangenotypic NS3/4A protease inhibitor.Antivir Ther2017; doi: 10.3851/IMP3202.
37.
LawitzE.J., Dvory-SobolH., DoehleB.P.Clinical resistance to velpatasvir (gs-5816), a novel pan-genotypic inhibitor of the hepatitis C virus NS5A protein.Antimicrob Agents Chemother2016; 60: 5368–5378.
38.
GallegoI., SheldonJ., MorenoE.Barrier-independent, fitness-associated differences in sofosbuvir efficacy against hepatitis C virus.Antimicrob Agents Chemother2016; 60: 3786–3793.
